olfactory receptor family 1 subfamily G member 1Genealiases: OR17-130 · OR17-209 · OR1G2
Q-omics provides the consensus-scored OR1G1 profile across patient tissues and cancer cell-line models. OR1G1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, OR1G1 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, OR1G1 RNA expression shows 8,609 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KIRC, and THYM as cancer lineages where OR1G1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR1G1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR1G1 survival associations across molecular data types. OR1G1 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR1G1 RNA expression–survival associations across cancer types. High OR1G1 expression shows unfavorable associations in MESO, KICH, ACC and SCLC, but favorable associations in CESC and UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for OR1G1 RNA expression.
This table summarizes OR1G1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for OR1G1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR1G1 shows higher tumor expression in KIRC, HNSC, BRCA, LUSC, LUAD and LIHC. The KIRC box plot shows higher OR1G1 RNA expression in tumor versus normal tissue (log2 FC = +0.046, t-test p < 0.001).
This table shows molecular features associated with OR1G1 in patient tissues and cancer cell lines. In patient samples, OR1G1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, OR1G1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BREAST.
